









Markets
/
Stocks
/
nasdaq-celu
/

Celularity Inc

CELU

View Detailed Chart

3.120USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

70.35MMarket Cap

LossP/E TTM



Celularity Inc

3.120

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-4.88%

5 Days

+5.41%

1 Month

+57.58%

6 Months

+54.46%

Year to Date

+50.00%

1 Year

+3.14%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(3)

Buy(5)

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.033

Buy

RSI(14)

58.554

Neutral

STOCH(KDJ)(9,3,3)

24.479

Sell

ATR(14)

0.454

High Vlolatility

CCI(14)

21.623

Neutral

Williams %R

52.564

Neutral

TRIX(12,20)

2.392

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.226

Sell

MA10

3.273

Sell

MA20

2.746

Buy

MA50

2.310

Buy

MA100

1.994

Buy

MA200

2.084

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).

Ticker SymbolCELU

CompanyCelularity Inc

CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.

Websitehttps://celularity.com/